Welcome to the e-CCO Library!

P604: Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: A prospective randomised trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

X. Roblin1*, S. Paul2, G. Boschetti3, J.M. Phelip4, E. Del Tedesco4, A. Berger5, S. Nancey3, N. Williet6, B. Flourie3

Created: Thursday, 21 February 2019, 9:14 AM
P604: Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Koo J.S., Kim D.J., Lee D.-W., Jeen Y.J.

Created: Wednesday, 20 February 2019, 10:36 AM
P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Cassieri1, R. Pica2, E.V. Avallone1, G. Brandimarte3, M. Zippi2, P. Crispino1, D. De Nitto2, P.G. Lecca3, P. Vernia1, R. Pica2, E.S. Corazziari1

Created: Thursday, 30 January 2020, 10:12 AM
P605: CRP reduction rate following initiation of anti-tumour necrosis factor-α induction therapy predicts secondary loss of response in patients with Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. H. Song*1, S. N. Hong1, T. J. Kim1, E. R. Kim1, D. K. Chang1, Y-H. Kim1

Created: Friday, 22 February 2019, 9:41 AM
P605: Development and validation of an objective disability index for Inflammatory Bowel Disease patients (ODIBD)
Year: 2021
Source: ECCO'21 Virtual
Authors: Melcarne, L.(1);Vergara Gómez, M.(1);Villoria Ferrer, A.(1);Brunet Mas, E.(1);Garcìa Iglesias, P.(1);Llovet Soto, L.(1);Dosal Galguera, A.(1);Monllor Nunell, T.(1);Alforcea Alcaraz, S.(1);Calvet Calvo, X.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P605: Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
Year: 2022
Source: ECCO'22
Authors: Jørgensen, K.K.(1); Syversen, S.W.(2); Jyssum, I.(2,3);Tveter, A.T.(2);Tran, T.T.(4);Sexton, J.(2);Provan, S.A.(2);Mjaaland , S.(5);Warren, D.J.(6);Kvien, T.K.(2,3);Grødeland , G.(3,4); Nissen-Meyer, L.S.(4);Ricanek, P.(1);Chopra , A.(4);Andersson, A.M.(4);Kro, G.B.(6);Jahnsen, J.(1,3);Munthe, L.A.(4,7);Haavardsholm, E.A.(2,3); Vaage, J.T.(3,4);Lund-Johansen, F.(3,8);Goll-, G.L.(2);
Created: Friday, 11 February 2022, 3:56 PM
P605: Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fiorino G.1, Ametzazurra A.2, Nagore D.*2, Hernández A.M.2, Torres N.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Pascual J.2, Recalde X.2, Martínez A.2, Danese S.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P605: Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Resál, T.(1);Bacsur, P.(2);Bor, R.(2);Bálint, A.(2);Katsanos, K.(3);Michalopoylos, G.(4);Ribaldone, D.G.(5);Attauabi, M.(6);Mirabella , Z.(7);Yanai, H.(8);Bezzio, C.(9);Castiglione, F.(10);Bar-Gil Shitrit, A.(11);Pugliese, D.(12);Lakatos, P.L.(13,14);Savarino, E.(15);Lukáš, M.(16);Franko, M.(17);Chashkova, E.(18);Molander, P.(19);Nancey, S.(20);Bannon, L.(21);Krznaric, Z.(22);Filip, R.(23);Szamosi, T.(24);Kaštylová, K.(25);Sarlós, P.(26);Ami-Barak, H.(8);Rispo, A.(27);Limdi, J.(28);Kagramanova, A.(29);Szepes, Z.(2);Farkas, K.(2);Molnár, T.(30)*;
Created: Friday, 14 July 2023, 11:05 AM
P605: Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international database
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, R. Hompes4, A. Spinelli6,7, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

Created: Thursday, 21 February 2019, 9:14 AM
P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Kakkadasam Ramaswamy1, R. Mutsekwa2, X. Lan2, Y. Chen2, R. Angus2, H. Moattar1, J. Edwards1, D. Shukla1

Created: Thursday, 30 January 2020, 10:12 AM
P606: Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ballester Ferré, M.P.(1);Mesonero, F.(2);Flórez-Diez, P.(3);Gómez, C.(1);Fuentes-Valenzuela, E.(4);Martín, N.(5);Senosiain, C.(2);Vela, M.(6);Fernández-Clotet, A.(7);Pérez, P.(8);Rubín de Célix, C.(9);Calviño-Suárez, C.(10);Ferreiro-Iglesias, R.(10);Hermida, B.(11);Muñoz, R.(12);González-Vivo, M.(13);Brunet, E.(14); Jiménez, N.(15);Botella, B.(16); Yebra, J.(17);Suárez, C.(18);Bouhmidi, A.(19);Jurado, R.M.(19);López, A.(20);Algarra, Á.(20);Besó, P.(20);Ponferrada, Á.(21);Plaza, R.(21);Dueñas, C.(22);Benítez, J.M.(23);Soto, P.(23);Castillo, E.(24); Iyo, E.(25);Carbonell-Asíns, J.A.(26);Beltran, B.(27);Mínguez, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P606: Health-related utility weights in Crohn's disease patients with perianal fistula
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Longworth1*, D. Fountain1, J. Singh1, I. Azzabi2, G. Owen3

Created: Thursday, 21 February 2019, 9:14 AM
P606: Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNFα in response to infliximab in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hellström P.M., Al-Saffar K.A., Tartera Diaz H., Ram G.V., Webb D.-L.

Created: Wednesday, 20 February 2019, 10:36 AM
P606: Significant regional differences in referral patterns for bowel resection in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iesalnieks, I.(1)*;Adamou, A.(2);Magdalena, B.(2);Streetz, K.(3);
Created: Friday, 14 July 2023, 11:05 AM
P606: Steroid use in inflammatory bowel disease patients on biological therapy in Montenegro
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Smolovic*1, M. Lukic1, O. Sekulic1, D. Muhovic1, V. Milosevic2, B. Vukcevic3

Created: Friday, 22 February 2019, 9:41 AM
P606: Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Otten , A.T.(1);Bourgonje , A.R.(1);Horinga , P.P.(1);van der Meulen , H.H.(1);van Leer-Buter , C.C.(2);Dijkstra , G.(1);Visschedijk , M.C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Schultz1, I. Diakite2, J. Carter2, S. Snedecor2, R. Turpin3

Created: Thursday, 30 January 2020, 10:12 AM
P607: Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Fischer1*, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, F. Koch1, A. Ramming2, S. Zundler1, D. Nagore3, W. Uter4, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
P607: Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open
Year: 2022
Source: ECCO'22
Authors: Rubin , D.T.(1);Vavricka , S.R.(2);Armuzzi , A.(3);Dubinsky , M.C.(4);Sharara , A.I.(5);Modesto , I.(6);Fellmann , M.(7);Liguori , G.(8);Lawendy , N.(9);Cadatal , M.J.(10);Lichtenstein , G.R.(11);
Created: Friday, 11 February 2022, 3:56 PM
P607: Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Narula1, B. Lauzon*1, J. Marshall1

Created: Friday, 22 February 2019, 9:41 AM